<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLOZARIL- clozapine tablet </strong><br>TYA Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use CLOZARIL safely and effectively. See full prescribing information for CLOZARIL.</span><br><span class="Bold">CLOZARIL® (clozapine) tablets, for oral use</span><br><span class="Bold">Initial U.S. Approval: 1989</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>: Can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Monitor white blood cell count and absolute neutrophil count prior to and during treatment. Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. ( , )
                                            <a href="#s2p1">2.1</a><a href="#s5p1">5.1</a></span></li>
<li><span class="Bold">Because of risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, CLOZARIL is available only through a restricted program called the CLOZARIL National Registry. Prescribers, patients, and pharmacies must enroll in the program. ( )
                                            <a href="#s5p2">5.2</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. ( , , )
                                            <a href="#s2p2">2.2</a><a href="#s2p5">2.5</a><a href="#s5p3">5.3</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. ( , )
                                            <a href="#s2p2">2.2</a><a href="#s5p4">5.4</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions. ( )
                                            <a href="#s5p5">5.5</a></span></li>
<li><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: CLOZARIL is not approved for this condition. ( )
                                            <a href="#s5p6">5.6</a></span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration ( , , )  
		     
	07/2013
                                    <a href="#s2p1">2.1</a><a href="#s2p6">2.6</a><a href="#s2p7">2.7</a> </p>
<p class="Highlighta">Contraindications ( )  
		     
	07/2013
                                    <a href="#s4">4</a> </p>
<p class="Highlighta">Warnings and Precautions ( , )  
		     
	07/2013
                                    <a href="#s5p2">5.2</a><a href="#s5p3">5.3</a> </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>: Can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Monitor white blood cell count and absolute neutrophil count prior to and during treatment. Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. ( , )
                                            <a href="#s2p1">2.1</a><a href="#s5p1">5.1</a></span></li>
<li><span class="Bold">Because of risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, CLOZARIL is available only through a restricted program called the CLOZARIL National Registry. Prescribers, patients, and pharmacies must enroll in the program. ( )
                                            <a href="#s5p2">5.2</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. ( , , )
                                            <a href="#s2p2">2.2</a><a href="#s2p5">2.5</a><a href="#s5p3">5.3</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. ( , )
                                            <a href="#s2p2">2.2</a><a href="#s5p4">5.4</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions. ( )
                                            <a href="#s5p5">5.5</a></span></li>
<li><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: CLOZARIL is not approved for this condition. ( )
                                            <a href="#s5p6">5.6</a></span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">CLOZARIL is an atypical antipsychotic indicated for: </p>
<ul class="Disc">
<li>Treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Efficacy was established in an active-controlled study. ( , )
                                        <a href="#s1p1">1.1</a><a href="#s14p1">14.1</a>
</li>
<li>Reducing <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>. Efficacy was established in an active-controlled study. ( , )
                                        <a href="#s1p2">1.2</a><a href="#s14p2">14.2</a>
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Starting Dose: 12.5 mg once daily or twice daily. ( )
                                        <a href="#s2p2">2.2</a>
</li>
<li>Use cautious titration and divided dosage schedule. ( , )
                                        <a href="#s2p2">2.2</a><a href="#s5p3">5.3</a>
</li>
<li>Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated. ( )
                                        <a href="#s2p2">2.2</a>
</li>
<li>Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks. ( )
                                        <a href="#s2p2">2.2</a>
</li>
<li>Subsequent increases: increase in increments of 100 mg or less, once or twice weekly. ( )
                                        <a href="#s2p2">2.2</a>
</li>
<li>Maximum daily dose: 900 mg ( )
                                        <a href="#s2p2">2.2</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">25 mg and 100 mg tablets with a facilitated score on one side ( )
                                    <a href="#s3">3</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>History of clozapine-induced <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span>. ( )
                                        <a href="#s4">4</a>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clozapine or any other component of CLOZARIL. ( )
                                        <a href="#s4">4</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Assess for organ involvement (e.g., <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>). Discontinue if these occur. ( )
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>:</span><a href="#s5p7">5.7</a>
</li>
<li>Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs). ( )
                                        <span class="Italics">QT Interval Prolongation:</span><a href="#s5p8">5.8</a>
</li>
<li>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include:
                                        <span class="Italics">Metabolic Changes:</span><br><br><ul>
<li>Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Monitor glucose regularly in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. ( )
                                                <span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus:</span><a href="#s5p9">5.9</a>
</li>
<li>Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics. ( )
                                                <span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>:</span><a href="#s5p9">5.9</a>
</li>
<li>Significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has occurred. Monitor <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. ( )
                                                <span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:</span><a href="#s5p9">5.9</a>
</li>
</ul>
</li>
<li>Immediately discontinue  and monitor closely. Assess for co-morbid conditions. ( )
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS):</span><a href="#s5p10">5.10</a>
</li>
<li>Evaluate for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, NMS. ( )
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>:</span><a href="#s5p11">5.11</a>
</li>
<li>Consider PE if <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> occur. ( )
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE):</span><a href="#s5p12">5.12</a>
</li>
<li>Use cautiously in presence of specific conditions (e.g., narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, use of anticholinergic drugs). ( )
                                        <span class="Italics">Anticholinergic Toxicity:</span><a href="#s5p13">5.13</a>
</li>
<li>Advise caution when operating machinery, including automobiles. ( )
                                        <span class="Italics">Interference with Cognitive and Motor Performance:</span><a href="#s5p14">5.14</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (≥5%) were: CNS reactions (sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>); cardiovascular reactions (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>); autonomic nervous system reactions (<span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>); gastrointestinal reactions (<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>); and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. ( )
                                    <a href="#s6p1">6.1</a><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Reduce CLOZARIL dose to one-third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin). ( , )
                                        <span class="Italics">Concomitant use of Strong CYP1A2 Inhibitors:</span><a href="#s2p6">2.6</a><a href="#s7p1">7.1</a>
</li>
<li>Concomitant use of is not recommended. ( , )
                                        <span class="Italics">Strong CYP3A4 Inducers</span><a href="#s2p6">2.6</a><a href="#s7p1">7.1</a>
</li>
<li>Consider reducing CLOZARIL dose when CYP1A2 (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. ( , )
                                        <span class="Italics">Discontinuation of CYP1A2 or CYP3A4 Inducers:</span><a href="#s2p6">2.6</a><a href="#s7p1">7.1</a>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul><li>Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother. ( )
                                        <span class="Italics">Nursing Mothers:</span><a href="#s8p3">8.3</a>
</li></ul>
<br><br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1     INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1     Treatment Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2     Reduction in the Risk of Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span></a></h2>
<h1><a href="#section-2" class="toc">2     DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1     Required Laboratory Testing Prior to Initiation and During Therapy</a></h2>
<h2><a href="#section-2.2" class="toc">2.2     Dosing Information</a></h2>
<h2><a href="#section-2.3" class="toc">2.3     Maintenance Treatment</a></h2>
<h2><a href="#section-2.4" class="toc">2.4     Discontinuation of Treatment</a></h2>
<h2><a href="#section-2.5" class="toc">2.5     Re-Initiation of Treatment</a></h2>
<h2><a href="#section-2.6" class="toc">2.6     Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers</a></h2>
<h2><a href="#section-2.7" class="toc">2.7     Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or CYP2D6 Poor Metabolizers</a></h2>
<h1><a href="#section-3" class="toc">3     DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4     CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5     WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1     <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2     CLOZARIL National Registry Because of the Risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3     <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5     <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6     Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7     <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8     QT Interval Prolongation</a></h2>
<h2><a href="#section-5.9" class="toc">5.9     Metabolic Changes</a></h2>
<h2><a href="#section-5.10" class="toc">5.10     <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12     <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13     Anticholinergic Toxicity</a></h2>
<h2><a href="#section-5.14" class="toc">5.14     Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-5.15" class="toc">5.15     <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16     Cerebrovascular Adverse Reactions</a></h2>
<h2><a href="#section-5.17" class="toc">5.17     Recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> and Cholinergic Rebound after Abrupt Discontinuation of CLOZARIL</a></h2>
<h1><a href="#section-6" class="toc">6     ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1     Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2     Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7     DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1     Potential for Other Drugs to Affect CLOZARIL</a></h2>
<h2><a href="#section-7.2" class="toc">7.2     Potential for CLOZARIL to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8     USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1     Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3     Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4     Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5     Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6     Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7     CYP2D6 Poor Metabolizers</a></h2>
<h1><a href="#section-9" class="toc">10     OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1     Overdosage Experience</a></h2>
<h2><a href="#section-9.2" class="toc">10.2     Management of Overdosage</a></h2>
<h1><a href="#section-10" class="toc">11     DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12     CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1     Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2     Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3     Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13     NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14     CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1     Treatment Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2     Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span></a></h2>
<h1><a href="#section-14" class="toc">16     HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1     How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2     Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17     PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="sbw"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span></p>
<p><span class="Bold">CLOZARIL treatment has caused <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, defined as an absolute neutrophil count (ANC) less than 500/mm . <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Prior to initiating treatment with CLOZARIL, obtain a baseline white blood cell (WBC) count  and ANC. The ANC must be greater than or equal to 2000/mm and the WBC must be greater than or equal to 3500/mm for a patient to begin treatment with CLOZARIL. During treatment, patients must have regular monitoring of ANC and WBC. Discontinue CLOZARIL and do not rechallenge if the ANC is less than 1000/mm or the WBC is less than 2000/mm . Advise patients to immediately report symptoms consistent with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>) .
                                <span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Italics">[see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]</span></span></p>
<p><span class="Bold">Because of the risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, CLOZARIL is available only through a restricted program called the CLOZARIL National Registry. Under the CLOZARIL National Registry, prescribers, patients, and pharmacies must enroll in the program .
                                <span class="Italics">[see Warnings and Precautions (5.2)]</span></span></p>
<p><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred with CLOZARIL treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages. Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (e.g., <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, use of antihypertensive medications) .
                                <span class="Italics">[see Dosage and Administration (2.2, and 2.5) and Warnings and Precautions (5.3)]</span></span></p>
<p><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have occurred with CLOZARIL treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering CLOZARIL to patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or other predisposing risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (CNS pathology, medications that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>). Caution patients about engaging in any activity where sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious risk to themselves or others .
                                <span class="Italics">[see Dosage and Administration (2.2), Warnings and Precautions (5.4)]</span></span></p>
<p><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></p>
<p><span class="Bold">Fatal <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> have occurred with CLOZARIL treatment.  Discontinue CLOZARIL and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with CLOZARIL-related <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> should not be rechallenged with CLOZARIL. Consider the possibility of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> if <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or ECG changes occur .
                                <span class="Italics">[see Warnings and Precautions (5.5)]</span></span></p>
<p><span class="Bold Underline">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></span></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. CLOZARIL is not approved for use in patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> .
                                <span class="Italics">[see Warnings and Precautions (5.6)]</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1     INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p1"></a><a name="section-1.1"></a><p></p>
<h2>1.1     Treatment Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First">CLOZARIL is indicated for the treatment of severely ill patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> who fail to respond adequately to standard antipsychotic treatment. Because of the significant risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment .
                                    <span class="Italics">[see Warnings and Precautions (5.1, 5.4)]</span></p>
<p>The effectiveness of CLOZARIL in treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing CLOZARIL and chlorpromazine in patients who had failed other antipsychotics .
                                    <span class="Italics">[see Clinical Studies (14.1)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p2"></a><a name="section-1.2"></a><p></p>
<h2>1.2     Reduction in the Risk of Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span></h2>
<p class="First">CLOZARIL is indicated for reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span> who are judged to be at chronic risk for re-experiencing <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, based on history and recent clinical state. <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> refers to actions by a patient that put him/herself at risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>The effectiveness of CLOZARIL in reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> was demonstrated over a 2-year treatment period in the InterSePT trial .
                                    <span class="Sup">TM</span><span class="Italics">[see Clinical Studies (14.2)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2     DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p1"></a><a name="section-2.1"></a><p></p>
<h2>2.1     Required Laboratory Testing Prior to Initiation and During Therapy</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Prior to initiating treatment with CLOZARIL, obtain a complete blood count (CBC) with differential. The absolute neutrophil count (ANC) must be greater than or equal to 2000/mm and the WBC must be greater than or equal to 3500 mm in order to initiate treatment. To continue treatment, the ANC and WBC must be monitored regularly .
                                        <span class="Sup">3</span><span class="Sup">3</span><span class="Italics">[see Warnings and Precautions (5.1)]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.2"></a><p></p>
<h2>2.2     Dosing Information</h2>
<p class="First">The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages .
                                    <span class="Italics">[see Warnings and Precautions (5.3)]</span></p>
<p>CLOZARIL can be taken with or without food .
                                    <span class="Italics">[see Pharmacokinetics (12.3)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.3"></a><p></p>
<h2>2.3     Maintenance Treatment</h2>
<p class="First">Generally, it is recommended that patients responding to CLOZARIL continue maintenance treatment on their effective dose beyond the acute episode.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p4"></a><a name="section-2.4"></a><p></p>
<h2>2.4     Discontinuation of Treatment</h2>
<p class="First">In the event of planned termination of CLOZARIL therapy, reduce the dose gradually over a period of 1 to 2 weeks. If abrupt discontinuation is necessary (because of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or another medical condition, for example), monitor carefully for the recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms and symptoms related to cholinergic rebound such as profuse <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p5"></a><a name="section-2.5"></a><p></p>
<h2>2.5     Re-Initiation of Treatment</h2>
<p class="First">When restarting CLOZARIL in patients who have discontinued CLOZARIL (i.e., 2 days or more since the last dose), re-initiate with 12.5-mg once daily or twice daily. This is necessary to minimize the risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> . If that dose is well tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment.
                                    <span class="Italics">[see Warnings and Precautions (5.3)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p6"></a><a name="section-2.6"></a><p></p>
<h2>2.6     Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2  inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John’s wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) .
                                        <span class="Italics">[see Drug Interactions (7)]</span></span></p>
<table>
<caption><span>Table 1. Dose Adjustment in Patients Taking Concomitant Medications</span></caption>
<col width="200">
<col width="200">
<col width="200">
<col width="200">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Comedications</span></td>
<td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Scenarios</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule">Initiating CLOZARIL while taking a comedication</td>
<td class="Lrule Rrule Toprule">Adding a comedication while taking CLOZARIL</td>
<td class="Lrule Rrule Toprule">Discontinuing a comedication while continuing CLOZARIL</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Strong CYP1A2 Inhibitors</td>
<td class="Lrule Rrule Toprule" colspan="2">Use one-third of the CLOZARIL dose.</td>
<td class="Lrule Rrule Toprule">Increase CLOZARIL dose based on clinical response.</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Moderate or Weak CYP1A2 Inhibitors</td>
<td class="Lrule Rrule Toprule" colspan="2">Monitor for adverse reactions. Consider reducing the CLOZARIL dose if necessary.
                                                <br>
</td>
<td class="Lrule Rrule Toprule" rowspan="2">Monitor for lack of effectiveness. Consider increasing CLOZARIL dose if necessary.</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">CYP2D6 or CYP3A4 Inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Strong CYP3A4 Inducers</td>
<td class="Lrule Rrule Toprule" colspan="2">Concomitant use is not recommended. However, if the inducer is necessary, it may be necessary to increase the CLOZARIL dose. Monitor for decreased effectiveness.
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule">Reduce CLOZARIL dose based on clinical response.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">Moderate or weak CYP1A2 or CYP3A4 Inducers</td>
<td class="Lrule Rrule Toprule" colspan="2">Monitor for decreased effectiveness. Consider increasing the CLOZARIL dose if necessary.</td>
<td class="Lrule Rrule Toprule">Monitor for adverse reactions. Consider reducing the CLOZARIL dose if necessary.
                                                <br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p7"></a><a name="section-2.7"></a><p></p>
<h2>2.7     Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or CYP2D6 Poor Metabolizers</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">It may be necessary to reduce the CLOZARIL dose in patients with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or in CYP2D6 poor metabolizers .
                                        <span class="Italics">[see Use in Specific Populations (8.6, 8.7)]</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3     DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">CLOZARIL (clozapine) is available as 25 mg and 100 mg round, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow, uncoated tablets with a facilitated score on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4     CONTRAINDICATIONS</h1>
<ul><li><span class="Bold" style="border-left:1px solid;"><span class="XmChange">History of Clozapine-induced <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> or Severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span></span></span></li></ul>
<p class="First" style="border-left:1px solid;"><span class="XmChange">CLOZARIL is contraindicated in patients with a history of clozapine-induced <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> .
                                <span class="Italics">[see Warnings and Precautions (5.1)]</span></span></p>
<ul><li><span class="Bold" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></span></li></ul>
<p style="border-left:1px solid;"><span class="XmChange">CLOZARIL is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clozapine (e.g., <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) or any other component of CLOZARIL .
                                <span class="Italics">[see Adverse Reactions (6.2)]</span></span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5     WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>5.1     <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First"><span class="Italics Underline">Background</span></p>
<p><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, defined as an ANC of less than 500/mm , has been estimated to occur in association with clozapine use at a cumulative incidence at 1 year of approximately 1.3%, based on the occurrence of 15 US cases out of 1743 patients exposed to CLOZARIL during its clinical testing prior to domestic marketing. All of these cases occurred at a time when the need for close monitoring of WBC counts was already recognized. A hematologic risk analysis was conducted based upon the available information in the CLOZARIL National Registry for US patients. Based upon a cut-off date of April 30, 1995, the incidence rates of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> based upon a weekly monitoring schedule rose steeply during the first 2 months of therapy, peaking in the third month. Among clozapine patients who continued the drug beyond the third month, the weekly incidence of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> fell a substantial degree. After 6 months, the weekly incidence of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> declines still further; however, it never reaches zero. It should be noted that any type of reduction in the frequency of monitoring WBC counts may result in an increased incidence of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.
                                    <span class="Sup">3</span></p>
<p><span class="Italics Underline">Risk Factors</span></p>
<p>Experience from clinical development, as well as from examples in the medical literature, suggests that patients who have developed <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> during clozapine therapy are at increased risk of subsequent episodes of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Analysis of WBC count data from the CLOZARIL National Registry also suggests that patients who have an initial episode of moderate <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (3000/mm &gt;WBC count ≥2000/mm ) are at an increased risk of subsequent episodes of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Except for bone-marrow suppression during initial clozapine therapy, there are no other established risk factors based on worldwide experience for the development of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> in association with clozapine use. However, a disproportionate number of the US cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> occurred in patients of Jewish background compared to the overall proportion of such patients exposed during domestic development of clozapine. Most of the US cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> occurred within 4–10 weeks of exposure, but neither dose nor duration is a reliable predictor of this problem. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> associated with other antipsychotic drugs has been reported to occur with a greater frequency in women, the elderly, and in patients who are cachectic or have serious underlying medical illness; such patients may also be at particular risk with clozapine, although this has not been definitively demonstrated.
                                    <span class="Sup">3</span><span class="Sup">3</span></p>
<p><span class="Italics Underline">WBC Count and ANC Clinical Monitoring Schedule</span></p>
<p>CLOZARIL is available only through a distribution system that ensures monitoring of WBC count and ANC according to the schedule described below prior to delivery of the next supply of medication.</p>
<p>As described in Table 2, patients who are being treated with CLOZARIL must have a baseline WBC count and ANC before initiation of treatment, and a WBC count and ANC every week for the first 6 months. Thereafter, if acceptable WBC counts and ANCs (WBC count ≥3500/mm and ANC ≥2000/mm ) have been maintained during the first 6 months of continuous therapy, WBC counts and ANCs can be monitored every 2 weeks for the next 6 months. Thereafter, if acceptable WBC counts and ANCs (WBC count ≥3500/mm and ANC ≥2000/mm ) have been maintained during the second 6 months of continuous therapy, WBC count and ANC can be monitored every 4 weeks.
                                    <span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span></p>
<p>When treatment with CLOZARIL is discontinued (regardless of the reason), WBC count and ANC must be monitored weekly for at least 4 weeks from the day of discontinuation or until WBC count ≥3500/mm and ANC ≥2000/mm .
                                    <span class="Sup">3</span><span class="Sup">3</span></p>
<p>Table 2 provides a summary of the frequency of monitoring that should occur based on various stages of therapy (e.g., initiation of therapy) or results from WBC count and ANC monitoring tests (e.g., moderate <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>). The text that follows should be consulted for additional details regarding the treatment of patients under the various conditions (e.g., severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>).</p>
<p>Advise patients to immediately report the appearance of signs/symptoms consistent with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>) at any time during CLOZARIL therapy. Such patients should have a WBC count and an ANC performed promptly.</p>
<table>
<caption><span>Table 2. Frequency of Monitoring Based on Stage of Therapy or Results from WBC Count and ANC Monitoring Tests</span></caption>
<col width="150">
<col width="250">
<col width="300">
<tfoot>
<tr class="First"><td colspan="3">WBC=White blood cell</td></tr>
<tr class="Last"><td colspan="3">ANC=Absolute neutrophil count</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Situation</span></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Hematological Values for Monitoring</span></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Frequency of WBC Count and ANC Monitoring</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Initiation of therapy</td>
<td class="Lrule Rrule Toprule">WBC count≥3500/mm and ANC≥2000/mm Note: Do not initiate in patients with a history of clozapine-induced <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>.
                                                <span class="Sup">3</span><br><br><span class="Sup">3</span><br>
</td>
<td class="Lrule Rrule Toprule">Weekly for 6 months</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">6 to 12 months of therapy</td>
<td class="Lrule Rrule Toprule">WBC ≥3500/mm and ANC ≥2000/mm
                                                <span class="Sup">3</span><br><br><span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule">Every 2 weeks for 6 months</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">12 months of therapy</td>
<td class="Lrule Rrule Toprule">WBC ≥3500/mm and ANC ≥2000/mm
                                                <span class="Sup">3</span><br><br><span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule">Every 4 weeks ad infinitum</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Immature forms present</td>
<td class="Lrule Rrule Toprule">N/A</td>
<td class="Lrule Rrule Toprule">Repeat WBC and ANC</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Discontinuation of therapy</td>
<td class="Lrule Rrule Toprule">N/A</td>
<td class="Lrule Rrule Toprule">Weekly for at least 4 weeks from day of discontinuation or until WBC ≥3500/mm and ANC ≥2000/mm
                                                <span class="Sup">3</span><span class="Sup">3</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Substantial drop in WBC or ANC</td>
<td class="Lrule Rrule Toprule">Single drop or cumulative drop within 3 weeks of: WBC ≥3000/mm or ANC ≥1500/mm
                                                <br><span class="Sup">3</span><br><span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule"><ol class="Arabic">
<li>Repeat WBC and ANC
                                                        <br>
</li>
<li>If repeat values are: WBC 3000/mm to 3500 and ANC &gt;2000/mm , then monitor twice weekly
                                                        <span class="Sup">3</span><span class="Sup">3</span>
</li>
</ol></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Mild <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or Mild <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule">If WBC 3000 mm to &lt;3500/mm and/or ANC 1500/mm to &lt;2000/mm
                                                <span class="Sup">3</span><br><span class="Sup">3</span><br><br><span class="Sup">3</span><br><span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule">Twice weekly until WBC &gt;3500/mm and ANC &gt;2000/mm then return to previous monitoring frequency
                                                <span class="Sup">3</span><span class="Sup">3</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Moderate <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or Moderate <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule">WBC 2000/mm to &lt;3000/mm and/or ANC 1000/mm to &lt;1500/mm
                                                <span class="Sup">3</span><br><span class="Sup">3</span><br><br><span class="Sup">3</span><br><span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule"><ol class="Arabic">
<li>Interrupt therapy
                                                        <br>
</li>
<li>Daily until WBC &gt;3000/mm and ANC &gt;1500/mm
                                                        <span class="Sup">3</span><span class="Sup">3</span><br>
</li>
<li>Twice weekly until WBC &gt;3500/mm and ANC &gt;2000/mm
                                                        <span class="Sup">3</span><span class="Sup">3</span><br>
</li>
<li>May rechallenge when WBC &gt;3500/mm and ANC &gt;2000/mm
                                                        <span class="Sup">3</span><span class="Sup">3</span><br>
</li>
<li>If rechallenged, monitor weekly for 1 year before returning to the usual monitoring schedule of every 2 weeks for 6 months and then every 4 weeks ad infinitum</li>
</ol></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or Severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule">WBC count &lt;2000/mm and/or ANC &lt;1000/mm
                                                <span class="Sup">3</span><br><br><span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule"><ol class="Arabic">
<li>Discontinue treatment and do not rechallenge patient
                                                        <br>
</li>
<li>Monitor until normal and for at least 4 weeks from day of discontinuation as follows:
                                                        <ul>
<li>Daily until WBC &gt;3000/mm and ANC &gt;1500/mm
                                                                <span class="Sup">3</span><span class="Sup">3</span>
</li>
<li>Twice weekly until WBC &gt;3500/mm and ANC &gt;2000/mm
                                                                <span class="Sup">3</span><span class="Sup">3</span>
</li>
<li>Weekly after WBC &gt;3500/mm
                                                                <span class="Sup">3</span>
</li>
</ul>
</li>
</ol></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></td>
<td class="Lrule Rrule Toprule">ANC &lt;500/mm
                                                <span class="Sup">3</span>
</td>
<td class="Lrule Rrule Toprule"><ol class="Arabic">
<li>Discontinue treatment and do not rechallenge patient
                                                        <br>
</li>
<li>Monitor until normal and for at least 4 weeks from day of discontinuation as follows:
                                                        <ul>
<li>Daily until WBC &gt;3000/mm and ANC &gt;1500/mm
                                                                <span class="Sup">3</span><span class="Sup">3</span>
</li>
<li>Twice weekly until WBC &gt;3500/mm and ANC &gt;2000/mm
                                                                <span class="Sup">3</span><span class="Sup">3</span>
</li>
<li>Weekly after WBC &gt;3500/mm
                                                                <span class="Sup">3</span>
</li>
</ul>
</li>
</ol></td>
</tr>
</tbody>
</table>
<p><span class="Italics Underline">Decrements in WBC Count and/or ANC</span></p>
<p>Consult Table 2 above to determine how to monitor patients who experience decrements in WBC count and/or ANC at any point during treatment. Additionally, patients should be carefully monitored for flu-like symptoms or other symptoms suggestive of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Italics Underline">Nonrechallengeable Patients</span></p>
<p>If the total WBC count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 2000/mm or the ANC <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 1000/mm , bone-marrow <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> should be considered to ascertain granulopoietic status and patients should not be rechallenged with clozapine. Protective isolation with close observation may be indicated if granulopoiesis is determined to be deficient. Should evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develop, the patient should have appropriate cultures performed and an appropriate antibiotic regimen instituted.
                                    <span class="Sup">3</span><span class="Sup">3</span></p>
<p>Patients discontinued from clozapine therapy due to significant granulopoietic suppression have been found to develop <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> upon rechallenge, often with a shorter latency on re-exposure. To reduce the chances of rechallenge occurring in patients who have experienced significant bone-marrow suppression during clozapine therapy, a single, national master file (i.e., Nonrechallengeable Database) is confidentially maintained.</p>
<p><span class="Italics Underline">Treatment of Rechallengeable Patients</span></p>
<p>Patients may be rechallenged with clozapine if their WBC count does not <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below 2000/mm and the ANC does not <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below 1000/mm . However, analysis of the data from the CLOZARIL National Registry suggests that patients who have an initial episode of moderate <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (3000/mm &gt;WBC count ≥2000/mm ) have up to a 12-fold increased risk of having a subsequent episode of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> when rechallenged as compared to the full cohort of patients treated with clozapine. Although CLOZARIL therapy may be resumed if no symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develop and when the WBC count rises above 3500/mm and the ANC rises above 2000/mm , prescribers are strongly advised to consider whether the benefit of continuing CLOZARIL treatment outweighs the increased risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.
                                    <span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span></p>
<p>Analyses of the CLOZARIL National Registry have shown an increased risk of having a subsequent episode of granulopoietic suppression up to a year after recovery from the initial episode. Therefore, as noted in Table 2, patients must undergo weekly WBC count and ANC monitoring for 1 year following recovery from an episode of moderate <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or moderate <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> regardless of when the episode develops. If acceptable WBC counts and ANC (WBC count ≥3500/mm and ANC ≥2000/mm ) have been maintained during the year of weekly monitoring, WBC counts can be monitored every 2 weeks for the next 6 months. If acceptable WBC counts and ANC (WBC count ≥3500/mm and ANC ≥2000/mm ) continue to be maintained during the 6 months of every 2-week monitoring, WBC counts can be monitored every 4 weeks thereafter, ad infinitum.
                                    <span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span><span class="Sup">3</span></p>
<p><span class="Italics Underline">Interruptions in Therapy</span></p>
<p>Figure 1 provides instructions regarding re-initiating therapy and subsequently the frequency of WBC count and ANC monitoring after a period of interruption.</p>
<p><span class="Bold">Figure 1.  Resuming Monitoring Frequency after Interruption of Therapy</span></p>
<div class="Figure"><img alt="Figure 1:  Resuming Monitoring Frequency after Interruption in Therapy" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cf63b13-48b2-4b07-b241-617725b52f6b&amp;name=clozaril-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2>5.2     CLOZARIL National Registry Because of the Risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Because of the risk of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, CLOZARIL is available only through a restricted program called the CLOZARIL National Registry. Under the CLOZARIL National Registry, prescribers, patients, pharmacies, and distributors must enroll in the program.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Required components of the CLOZARIL National Registry are:</span></p>
<ul class="Disc">
<li style="border-left:1px solid;"><span class="XmChange">Healthcare professionals who prescribe CLOZARIL must enroll in the program and comply with the Registry requirements.</span></li>
<li style="border-left:1px solid;"><span class="XmChange">Pharmacies that dispense CLOZARIL must enroll in the program and comply with the Registry requirements.</span></li>
<li style="border-left:1px solid;"><span class="XmChange">Routine monitoring and submission of laboratory results (WBC and ANC) is required during treatment with CLOZARIL .
                                            <span class="Italics">[see Warnings and Precautions (5.1)]</span></span></li>
<li style="border-left:1px solid;"><span class="XmChange">Patients who receive CLOZARIL must be enrolled in a registry.</span></li>
</ul>
<p style="border-left:1px solid;"><span class="XmChange">Further information is available at or 1-888-669-6682.
                                        <a href="http://www.clozarilregistry.com">http://www.clozarilregistry.com</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>5.3     <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally mediated <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">reflex bradycardia</span> (NMRB).</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions . Consider reducing the dose if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs. When restarting patients who have had even a brief interval off CLOZARIL (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily .
                                        <span class="Italics">[see Dosage and Administration (2.2)]</span><span class="Italics">[see Dosage and Administration (2.5)]</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Use CLOZARIL cautiously in patients with cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (e.g., concomitant use of antihypertensives, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2>5.4     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> has been estimated to occur in association with clozapine use at a cumulative incidence at 1 year of approximately 5%, based on the occurrence of 1 or more <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in 61 of 1743 patients exposed to clozapine during its clinical testing prior to domestic marketing (i.e., a crude rate of 3.5%). The risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> is dose-related. Initiate treatment with a low dose (12.5 mg), titrate slowly, and use divided dosing.</p>
<p>Use caution when administering CLOZARIL to patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or other predisposing risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (e.g., head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or other CNS pathology, use of medications that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>). Because of the substantial risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> associated with CLOZARIL use, caution patients about engaging in any activity where sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious risk to themselves or others (e.g., driving an automobile, operating complex machinery, swimming, climbing).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2>5.5     <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> have occurred with the use of CLOZARIL. These reactions can be fatal. Discontinue CLOZARIL and obtain a cardiac evaluation upon suspicion of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. Generally, patients with a history of clozapine-associated <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> should not be rechallenged with CLOZARIL. However, if the benefit of CLOZARIL treatment is judged to outweigh the potential risks of recurrent <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, the clinician may consider rechallenge with CLOZARIL in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.</p>
<p>Consider the possibility of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> in patients receiving CLOZARIL who present with <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, persistent <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> at rest, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, other signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or electrocardiographic findings (low voltages, ST-T abnormalities, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, right axis deviation, and poor R wave progression). <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> most frequently presents within the first 2 months of clozapine treatment. Symptoms of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> generally occur later than clozapine-associated <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and usually after 8 weeks of treatment. However, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> can occur at any period during treatment with CLOZARIL. It is common for nonspecific flu-like symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, pleuritic <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and low-grade <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> to precede more overt signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Typical laboratory findings include elevated <span class="product-label-link" type="condition" conceptid="4010039" conceptname="Troponin I">troponin I</span> or T, elevated creatinine kinase-MB, peripheral <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and elevated C-reactive protein (CRP). Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionucleotide studies, or cardiac catheterization) may reveal evidence of <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p6"></a><a name="section-5.6"></a><p></p>
<h2>5.6     Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in this population. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. CLOZARIL is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> .
                                    <span class="Italics">[see Boxed Warning]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p7"></a><a name="section-5.7"></a><p></p>
<h2>5.7     <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, defined as a blood eosinophil count of greater than 700/mm , has occurred with CLOZARIL treatment. In clinical trials, approximately 1% of patients developed <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. Clozapine-related <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> usually occurs during the first month of treatment. In some patients, it has been associated with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, and <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. Such organ involvement could be consistent with a drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS) syndrome, also known as drug induced <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> (DIHS). If <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> develops during CLOZARIL treatment, evaluate promptly for signs and symptoms of systemic reactions, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other allergic symptoms, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, or other organ-specific disease associated with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. If CLOZARIL-related systemic disease is suspected, discontinue CLOZARIL immediately.
                                    <span class="Sup">3</span></p>
<p>If a cause of <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> unrelated to CLOZARIL is identified (e.g., <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, allergies, collagen vascular disease, parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and specific neoplasms), treat the underlying cause and continue CLOZARIL.</p>
<p>Clozapine-related <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> has also occurred in the absence of organ involvement and can resolve without intervention. There are reports of successful rechallenge after discontinuation of clozapine, without recurrence of <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. In the absence of organ involvement, continue CLOZARIL under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt CLOZARIL therapy and rechallenge after the eosinophil count decreases should be based on the overall clinical assessment, in consultation with an internist or hematologist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p8"></a><a name="section-5.8"></a><p></p>
<h2>5.8     QT Interval Prolongation</h2>
<p class="First">QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> and other life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred with CLOZARIL treatment. When prescribing CLOZARIL, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, family history of <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> or <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span>, significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities.</p>
<p>Prior to initiating treatment with CLOZARIL, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue CLOZARIL if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>, or other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, (e.g., <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>), obtain a cardiac evaluation and discontinue CLOZARIL.</p>
<p>Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of CLOZARIL. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Clozapine is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of CLOZARIL .
                                    <span class="Italics">[see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]</span></p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> increase the risk of QT prolongation. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can result from diuretic therapy, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and other causes. Use caution when treating patients at risk for significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbance</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with CLOZARIL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p9"></a><a name="section-5.9"></a><p></p>
<h2>5.9     Metabolic Changes</h2>
<p class="First">Atypical antipsychotic drugs, including CLOZARIL have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics including CLOZARIL. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with atypical antipsychotics are not available.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on CLOZARIL should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.</p>
<p>In a pooled data analysis of 8 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean changes in fasting glucose concentration in the CLOZARIL and chlorpromazine groups were +11 mg/dL and +4 mg/dL respectively. A higher proportion of the CLOZARIL group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 3). The CLOZARIL doses were 100–900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for CLOZARIL and chlorpromazine.</p>
<table>
<caption><span>Table 3. Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col width="180">
<col width="240">
<col width="240">
<col width="180">
<col width="180">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Laboratory Parameter</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Category Change (at least once) from baseline</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Treatment Arm</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">n (%)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" rowspan="4">Fasting Glucose</td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Normal (&lt;100 mg/dL) to High (≥126 mg/dL)
                                                <br><br><br>
</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">198</td>
<td class="Lrule Rrule Toprule" align="center">53 (27)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">135</td>
<td class="Lrule Rrule Toprule" align="center">14 (10)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Borderline (100 to 125 mg/dL) to High (≥126 mg/dL)
                                                <br><br><br>
</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">57</td>
<td class="Lrule Rrule Toprule" align="center">24 (42)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">43</td>
<td class="Lrule Rrule Toprule" align="center">12 (28)</td>
</tr>
<tr class="Last"><td class="Lrule Rrule Toprule" align="center" colspan="5"></td></tr>
</tbody>
</table>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></p>
<p>Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including CLOZARIL. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using CLOZARIL, is recommended.</p>
<p>In a pooled data analysis of 10 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, CLOZARIL treatment was associated with increases in serum total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. No data were collected on LDL and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. The mean increase in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 13 mg/dL in the CLOZARIL group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, CLOZARIL treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the CLOZARIL group and 39 mg/dL (35%) in the chlorpromazine group (Table 4). In addition, CLOZARIL treatment was associated with categorical increases in serum total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride, as illustrated in Table 5.The proportion of patients with categorical increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or fasting triglyceride increased with the duration of exposure. The median duration of CLOZARIL and chlorpromazine exposure was 45 days and 38 days, respectively. The CLOZARIL dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.</p>
<table>
<caption><span>Table 4. Mean Changes in Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and Triglyceride Concentration in Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col width="240">
<col width="240">
<col width="240">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Treatment Arm</span></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Baseline total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration (mg/dL)</span></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Change from baseline mg/dL (%)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">CLOZARIL (N=334)</td>
<td class="Lrule Rrule Toprule">184</td>
<td class="Lrule Rrule Toprule">+13 (7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Chlorpromazine (185)</td>
<td class="Lrule Rrule Toprule">182</td>
<td class="Lrule Rrule Toprule">+15 (8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Baseline triglyceride concentration (mg/dL)</span></td>
<td class="Lrule Rrule Toprule"><span class="Bold">Change from baseline mg/dL (%)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">CLOZARIL (N=6)</td>
<td class="Lrule Rrule Toprule">130</td>
<td class="Lrule Rrule Toprule">+71 (54)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">Chlorpromazine (N=7)</td>
<td class="Lrule Rrule Toprule">110</td>
<td class="Lrule Rrule Toprule">+39 (35)</td>
</tr>
</tbody>
</table>
<table>
<caption><span>Table 5. Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col width="200">
<col width="240">
<col width="200">
<col width="160">
<col width="160">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Laboratory Parameter
                                                    <br></span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Category Change (at least once) from baseline</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Treatment Arm
                                                    <br></span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">n (%)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="6">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (random or fasting)
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Increase by ≥40 mg/dL</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">334</td>
<td class="Lrule Rrule Toprule" align="center">111 (33)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">185</td>
<td class="Lrule Rrule Toprule" align="center">46 (25)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Normal (&lt;200 mg/dL) to High (≥240 mg/dL)
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">222</td>
<td class="Lrule Rrule Toprule" align="center">18 (8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">132</td>
<td class="Lrule Rrule Toprule" align="center">3 (2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Borderline (200-239 mg/dL) to High (≥240 mg/dL)
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">79</td>
<td class="Lrule Rrule Toprule" align="center">30 (38)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">34</td>
<td class="Lrule Rrule Toprule" align="center">14 (41)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="6">Triglycerides (fasting)
                                                <br>
</td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Increase by ≥50 mg/dL</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">6</td>
<td class="Lrule Rrule Toprule" align="center">3 (50)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">7</td>
<td class="Lrule Rrule Toprule" align="center">3 (43)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Normal (&lt;150 mg/dL) to High (≥200 mg/dL)
                                                <br><br>
</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">4</td>
<td class="Lrule Rrule Toprule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">6</td>
<td class="Lrule Rrule Toprule" align="center">2 (33)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="2">Borderline (≥150 mg/dL and &lt;200 mg/dL) to High (≥200 mg/dL)
                                                <br><br><br>
</td>
<td class="Lrule Rrule Toprule" align="center">CLOZARIL</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
<td class="Lrule Rrule Toprule" align="center">1 (100)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Chlorpromazine</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
<td class="Lrule Rrule Toprule" align="center">0 (0)</td>
</tr>
<tr class="Last"><td class="Lrule Rrule Toprule" align="center" colspan="5"></td></tr>
</tbody>
</table>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has occurred with the use of antipsychotics, including CLOZARIL. Monitor weight during treatment with CLOZARIL. Table 6 summarizes the data on <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> by the duration of exposure pooled from 11 studies with CLOZARIL and active comparators. The median duration of exposure was 609, 728, and 42 days, in the CLOZARIL, olanzapine, and chlorpromazine group, respectively.</p>
<table>
<caption><span>Table 6. Mean Change in Body Weight (kg) by duration of exposure from studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span></span></caption>
<col width="240">
<col width="240">
<col width="100">
<col width="100">
<col width="100">
<col width="100">
<col width="100">
<col width="100">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" rowspan="2"><span class="Bold">Metabolic parameter</span></td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2"><span class="Bold">Exposure duration</span></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">CLOZARIL (N=669)
                                                    <br></span></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Olanzapine (N=442)
                                                    <br></span></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Chlorpromazine (N=155)
                                                    <br></span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">n</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Mean</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">n</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Mean</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">n</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Mean</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="6"><span class="Bold">Weight change from baseline</span></td>
<td class="Lrule Rrule Toprule" align="center">2 weeks (Day 11–17)</td>
<td class="Lrule Rrule Toprule" align="center">6</td>
<td class="Lrule Rrule Toprule" align="center">+0.9</td>
<td class="Lrule Rrule Toprule" align="center">3</td>
<td class="Lrule Rrule Toprule" align="center">+0.7</td>
<td class="Lrule Rrule Toprule" align="center">2</td>
<td class="Lrule Rrule Toprule" align="center">-0.5</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">4 weeks (Day 21–35)</td>
<td class="Lrule Rrule Toprule" align="center">23</td>
<td class="Lrule Rrule Toprule" align="center">+0.7</td>
<td class="Lrule Rrule Toprule" align="center">8</td>
<td class="Lrule Rrule Toprule" align="center">+0.8</td>
<td class="Lrule Rrule Toprule" align="center">17</td>
<td class="Lrule Rrule Toprule" align="center">+0.6</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">8 weeks (Day 49–63)</td>
<td class="Lrule Rrule Toprule" align="center">12</td>
<td class="Lrule Rrule Toprule" align="center">+1.9</td>
<td class="Lrule Rrule Toprule" align="center">13</td>
<td class="Lrule Rrule Toprule" align="center">+1.8</td>
<td class="Lrule Rrule Toprule" align="center">16</td>
<td class="Lrule Rrule Toprule" align="center">+0.9</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">12 weeks (Day 70–98)</td>
<td class="Lrule Rrule Toprule" align="center">17</td>
<td class="Lrule Rrule Toprule" align="center">+2.8</td>
<td class="Lrule Rrule Toprule" align="center">5</td>
<td class="Lrule Rrule Toprule" align="center">+3.1</td>
<td class="Lrule Rrule Toprule" align="center">0</td>
<td class="Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">24 weeks (154–182)</td>
<td class="Lrule Rrule Toprule" align="center">42</td>
<td class="Lrule Rrule Toprule" align="center">- 0.6</td>
<td class="Lrule Rrule Toprule" align="center">12</td>
<td class="Lrule Rrule Toprule" align="center">+5.7</td>
<td class="Lrule Rrule Toprule" align="center">0</td>
<td class="Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">48 weeks (Day 322–350)</td>
<td class="Lrule Rrule Toprule" align="center">3</td>
<td class="Lrule Rrule Toprule" align="center">+3.7</td>
<td class="Lrule Rrule Toprule" align="center">3</td>
<td class="Lrule Rrule Toprule" align="center">+13.7</td>
<td class="Lrule Rrule Toprule" align="center">0</td>
<td class="Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr class="Last"><td class="Lrule Rrule Toprule" colspan="8"></td></tr>
</tbody>
</table>
<p>Table 7 summarizes pooled data from 11 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> demonstrating <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> ≥7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the CLOZARIL, olanzapine, and chlorpromazine group, respectively.</p>
<table>
<caption><span>Table 7. Proportion of Adult Subjects in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Studies with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> ≥7% Relative to Baseline Body Weight</span></caption>
<col width="200">
<col width="200">
<col width="200">
<col width="200">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Weight change</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">CLOZARIL</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Olanzapine</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Chlorpromazine</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N</span></td>
<td class="Lrule Rrule Toprule" align="center">669</td>
<td class="Lrule Rrule Toprule" align="center">442</td>
<td class="Lrule Rrule Toprule" align="center">155</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">≥7% (inclusive)</span></td>
<td class="Lrule Rrule Toprule" align="center">236 (35%)</td>
<td class="Lrule Rrule Toprule" align="center">203 (46%)</td>
<td class="Lrule Rrule Toprule" align="center">13 (8%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p10"></a><a name="section-5.10"></a><p></p>
<h2>5.10     <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">Antipsychotic drugs including CLOZARIL can cause a potentially fatal symptom complex referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS). Clinical manifestations of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>). Associated findings can include elevated creatine phosphokinase (CPK), <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, primary CNS pathology, central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>).</p>
<p>The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of comorbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.</p>
<p>NMS has occurred with CLOZARIL monotherapy and with concomitant CNS-active medications, including lithium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p11"></a><a name="section-5.11"></a><p></p>
<h2>5.11     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First">During clozapine therapy, patients have experienced transient, clozapine-related <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The peak incidence is within the first 3 weeks of treatment. While this <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> is generally benign and self-limited, it may necessitate discontinuing treatment. The <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> can be associated with an increase or decrease in WBC count. Carefully evaluate patients with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> to rule out <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Consider the possibility of NMS .
                                    <span class="Italics">[see Warnings and Precautions (5.10)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p12"></a><a name="section-5.12"></a><p></p>
<h2>5.12     <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> have occurred in patients treated with CLOZARIL. Consider the possibility of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> in patients who present with deep-vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">acute dyspnea</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or with other respiratory signs and symptoms. Whether <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> can be attributed to clozapine or some characteristic(s) of patients is not clear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p13"></a><a name="section-5.13"></a><p></p>
<h2>5.13     Anticholinergic Toxicity</h2>
<p class="First">CLOZARIL has potent anticholinergic effects. Treatment with CLOZARIL can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, concomitant anticholinergic medications, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or other conditions in which anticholinergic effects can lead to significant adverse reactions.</p>
<p>Treatment with CLOZARIL can result in gastrointestinal adverse reactions, including <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, and <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. Such reactions can be fatal. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p14"></a><a name="section-5.14"></a><p></p>
<h2>5.14     Interference with Cognitive and Motor Performance</h2>
<p class="First">CLOZARIL can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that CLOZARIL does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p15"></a><a name="section-5.15"></a><p></p>
<h2>5.15     <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> (TD) has occurred in patients treated with antipsychotic drugs, including CLOZARIL. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe CLOZARIL in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with CLOZARIL despite the presence of the syndrome.</p>
<p>There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p16"></a><a name="section-5.16"></a><p></p>
<h2>5.16     Cerebrovascular Adverse Reactions</h2>
<p class="First">In controlled trials, elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for CLOZARIL or other antipsychotics or other patient populations. CLOZARIL should be used with caution in patients with risk factors for cerebrovascular adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p17"></a><a name="section-5.17"></a><p></p>
<h2>5.17     Recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> and Cholinergic Rebound after Abrupt Discontinuation of CLOZARIL</h2>
<p class="First">If abrupt discontinuation of CLOZARIL is necessary (because of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or another medical condition, for example), monitor carefully for the recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms and adverse reactions related to cholinergic rebound, such as profuse <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6     ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> .
                                <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> .
                                <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> .
                                <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> .
                                <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</li>
<li>Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> .
                                <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> .
                                <span class="Italics">[see Warnings and Precautions (5.7)]</span>
</li>
<li>QT Interval Prolongation .
                                <span class="Italics">[see Warnings and Precautions (5.8)]</span>
</li>
<li>Metabolic Changes (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>) .
                                <span class="Italics">[see Warnings and Precautions (5.9)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> .
                                <span class="Italics">[see Warnings and Precautions (5.10)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> .
                                <span class="Italics">[see Warnings and Precautions (5.11)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> .
                                <span class="Italics">[see Warnings and Precautions (5.12)]</span>
</li>
<li>Anticholinergic Toxicity .
                                <span class="Italics">[see Warnings and Precautions (5.13)]</span>
</li>
<li>Interference with Cognitive and Motor Performance .
                                <span class="Italics">[see Warnings and Precautions (5.14)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> .
                                <span class="Italics">[see Warnings and Precautions (5.15)]</span>
</li>
<li>Cerebrovascular Adverse Reactions .
                                <span class="Italics">[see Warnings and Precautions (5.16)]</span>
</li>
<li>Recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> and Cholinergic Rebound after Abrupt Discontinuation .
                                <span class="Italics">[see Warnings and Precautions (5.17)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p1"></a><a name="section-6.1"></a><p></p>
<h2>6.1     Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most commonly reported adverse reactions (&gt;5%) across CLOZARIL clinical trials were: CNS reactions, including sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>; cardiovascular reactions, including <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; autonomic nervous system reactions, including <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; gastrointestinal reactions, including <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Table 8 summarizes the most commonly reported adverse reactions (&gt;5%) in CLOZARIL-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<table>
<caption><span>Table 8. Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col width="250">
<col width="100">
<col width="100">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Adverse Reaction</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">CLOZARIL (N=126) (%)
                                                    <br><br></span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Chlorpromazine (N=142) (%)
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Sedation</span></td>
<td class="Lrule Rrule Toprule" align="center">21</td>
<td class="Rrule Toprule" align="center">13</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></span></td>
<td class="Lrule Rrule" align="center">17</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></td>
<td class="Lrule Rrule" align="center">16</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></span></td>
<td class="Lrule Rrule" align="center">14</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Rrule" align="center">38</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (<span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>)</span></td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Hypersalivation</span></span></td>
<td class="Lrule Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></td>
<td class="Lrule Rrule" align="center">12</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr>
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span></td>
<td class="Lrule Rrule" align="center">10</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Last">
<td class="Lrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></span></td>
<td class="Lrule Rrule" align="center">5</td>
<td class="Rrule" align="center">20</td>
</tr>
</tbody>
</table>
<p>Table 9 summarizes the adverse reactions reported in CLOZARIL-treated patients at a frequency of 2% or greater across all CLOZARIL studies (excluding the 2-year InterSePT™ Study). These rates are not adjusted for duration of exposure.</p>
<table>
<caption><span>Table 9. Adverse Reactions (≥2%) Reported in CLOZARIL-treated Patients (N=842) Across all CLOZARIL Studies (excluding the 2-year InterSePT Study)
                                        <span class="Sup">TM</span></span></caption>
<col width="250">
<col width="150">
<tfoot><tr class="First Last"><td colspan="2">†	Rate based on population of approximately 1700 exposed during premarket 
clinical evaluation of CLOZARIL.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Body System      Adverse Reaction*
                                                    <br></span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">CLOZARIL N=842 Percentage of Patients
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Central Nervous System</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>/Sedation</td>
<td class="Rrule" align="center">39</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Rrule" align="center">19</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule">     Disturbed Sleep/<span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmares</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span>/<span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">Akinesia</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>)</td>
<td class="Rrule" align="center">3†</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Rigidity</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Cardiovascular</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center">25†</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">9</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">14</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span>/<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Urogenital</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     Urinary Abnormalities</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Autonomic Nervous System</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivation</span></td>
<td class="Rrule" align="center">31</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbances</span></td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Skin</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Hemic/Lymphatic</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/Decreased WBC/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Miscellaneous</span></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Last">
<td class="Lrule">     <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></td>
<td class="Rrule" align="center">4</td>
</tr>
</tbody>
</table>
<p>Table 10 summarizes the most commonly reported adverse reactions (&gt;10% of the CLOZARIL or olanzapine group) in the InterSePT Study. This was an adequate and well-controlled, 2-year study evaluating the efficacy of CLOZARIL relative to olanzapine in reducing the risk of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>. The rates are not adjusted for duration of exposure.
                                    <span class="Sup">TM</span></p>
<table>
<caption><span>Table 10. Incidence of Adverse Reactions in Patients Treated with CLOZARIL or Olanzapine in the InterSePT Study (&gt;10% in the CLOZARIL or olanzapine group)
                                        <span class="Sup">TM</span></span></caption>
<col width="225">
<col width="150">
<col width="150">
<tbody class="Headless">
<tr class="First">
<td valign="bottom"><span class="Bold">Adverse Reactions</span></td>
<td align="center" valign="bottom">
<span class="Bold">CLOZARIL</span><span class="Bold">N=479
                                                    <br></span><span class="Bold">% Reporting
                                                    <br></span>
</td>
<td align="center" valign="bottom">
<span class="Bold">Olanzapine</span><br><span class="Bold">N=477</span><span class="Bold">% Reporting
                                                    <br></span>
</td>
</tr>
<tr>
<td class="Toprule" valign="bottom"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td class="Toprule" align="center" valign="bottom">48</td>
<td class="Toprule" align="center" valign="bottom">6</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="bottom">46</td>
<td align="center" valign="bottom">25</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td align="center" valign="bottom">31</td>
<td align="center" valign="bottom">56</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">10</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">33</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">10</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">9</td>
</tr>
<tr class="Last">
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">8</td>
</tr>
</tbody>
</table>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></span></p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.
                                    <span class="Italics">Class effect:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p2"></a><a name="section-6.2"></a><p></p>
<h2>6.2     Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of clozapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics Underline">Central Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">Delirium</span>, <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">EEG abnormal</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, possible <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions.</p>
<p><span class="Italics Underline">Cardiovascular System</span></p>
<p>Atrial or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, QT interval prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>.</p>
<p><span class="Italics Underline">Gastrointestinal System</span></p>
<p><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="28461" conceptname="Hypertrophy of salivary gland">salivary gland swelling</span>.</p>
<p><span class="Italics Underline">Hepatobiliary System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">Cholestasis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (hepatic, cholestatic, and mixed), and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
<p><span class="Italics Underline">Urogenital System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><span class="Italics Underline">Skin</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>.</p>
<p><span class="Italics Underline">Musculoskeletal System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">Myasthenic syndrome</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Italics Underline">Respiratory System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">Aspiration</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>.</p>
<p><span class="Italics Underline">Hemic and Lymphatic System</span></p>
<p>Deep-vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, elevated hemoglobin/hematocrit, <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span> (ESR) increased, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics Underline">Vision Disorders</span></p>
<p>Narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p><span class="Italics Underline">Miscellaneous</span></p>
<p>Creatine phosphokinase elevation, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7     DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p1"></a><a name="section-7.1"></a><p></p>
<h2>7.1     Potential for Other Drugs to Affect CLOZARIL</h2>
<p class="First">Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering CLOZARIL concomitantly with drugs that are inducers or inhibitors of these enzymes.</p>
<p><span class="Italics Underline">CYP1A2 Inhibitors</span></p>
<p>Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued .
                                    <span class="Italics">[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)]</span></p>
<p>Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when CLOZARIL is coadministered with these inhibitors. Consider reducing the CLOZARIL dosage if necessary .
                                    <span class="Italics">[see Dosage and Administration (2.6)]</span></p>
<p><span class="Italics Underline">CYP2D6 and CYP3A4 Inhibitors</span></p>
<p>Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions . Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose .
                                    <span class="Italics">[see Clinical Pharmacology (12.3)]</span><span class="Italics">[see Dosage and Administration (2.6)]</span></p>
<p><span class="Italics Underline">CYP1A2 and CYP3A4 Inducers</span></p>
<p>Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of CLOZARIL. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John’s wort, and rifampin. It may be necessary to increase the CLOZARIL dose if used concomitantly with inducers of these enzymes. However, concomitant use of CLOZARIL and strong CYP3A4 inducers is not recommended .
                                    <span class="Italics">[see Dosage and Administration (2.6)]</span></p>
<p>Consider reducing the CLOZARIL dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions .
                                    <span class="Italics">[see Dosage and Administration (2.6)]</span></p>
<p><span class="Italics Underline">Drugs that Cause QT Interval Prolongation</span></p>
<p>Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) .
                                    <span class="Italics">[see Warnings and Precautions (5.8)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p2"></a><a name="section-7.2"></a><p></p>
<h2>7.2     Potential for CLOZARIL to Affect Other Drugs</h2>
<p class="First">Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYPD26 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8     USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1     Pregnancy</h2>
<p class="First">Pregnancy Category B</p>
<p><span class="Underline">Risk Summary</span></p>
<p>There are no adequate or well-controlled studies of clozapine in pregnant women.</p>
<p>Reproduction studies have been performed in rats and rabbits at doses up to 0.4 and 0.9 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m body surface area basis. The studies revealed no evidence of impaired fertility or harm to the fetus due to clozapine. Because animal reproduction studies are not always predictive of human response, CLOZARIL should be used during pregnancy only if clearly needed.
                                    <span class="Sup">2</span></p>
<p><span class="Underline">Clinical Considerations</span></p>
<p>Consider the risk of exacerbation of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> when discontinuing or changing treatment with antipsychotic medications during pregnancy and postpartum. Consider early screening for <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> for patients treated with antipsychotic medications . Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, and feeding difficulties. The severity of complications can vary from self-limited symptoms to some neonates requiring intensive care unit support and prolonged hospitalization.
                                    <span class="Italics">[see Warnings and Precautions (5.9)]</span></p>
<p><span class="Underline">Animal Data</span></p>
<p>In embryofetal developmental studies, clozapine had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m body surface area basis.
                                    <span class="Sup">2</span></p>
<p>In peri/postnatal developmental studies, pregnant female rats were administered clozapine over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Clozapine caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m body surface area basis.
                                    <span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.2"></a><p></p>
<h2>8.3     Nursing Mothers</h2>
<p class="First">CLOZARIL is present in human milk. Because of the potential for serious adverse reactions in nursing infants from CLOZARIL, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8p4"></a><a name="section-8.3"></a><p></p>
<h2>8.4     Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8p5"></a><a name="section-8.4"></a><p></p>
<h2>8.5     Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric patients in clinical studies utilizing CLOZARIL to determine whether those over 65 years of age differ from younger subjects in their response to CLOZARIL.</p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> can occur with CLOZARIL treatment . Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects.
                                    <span class="Italics">[see Boxed Warning and Warnings and Precautions (5.3)]</span></p>
<p>Elderly patients may be particularly susceptible to the anticholinergic effects of CLOZARIL, such as <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> .
                                    <span class="Italics">[see Warnings and Precautions (5.13)]</span></p>
<p>Carefully select CLOZARIL doses in elderly patients, taking into consideration their greater frequency of decreased hepatic, renal, or cardiac function, as well as other concomitant disease and other drug therapy. Clinical experience suggests that the prevalence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appears to be highest among the elderly; especially elderly women .
                                    <span class="Italics">[see Warnings and Precautions (5.15)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p6"></a><a name="section-8.5"></a><p></p>
<h2>8.6     Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted .
                                    <span class="Italics">[see Dosage and Administration (2.7), Clinical Pharmacology (12.3)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p7"></a><a name="section-8.6"></a><p></p>
<h2>8.7     CYP2D6 Poor Metabolizers</h2>
<p class="First">Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted .
                                    <span class="Italics">[see Dosage and Administration (2.7), Clinical Pharmacology (12.3)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10     OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>10.1     Overdosage Experience</h2>
<p class="First">The most commonly reported signs and symptoms associated with clozapine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are: sedation, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or failure; and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>. There are reports of <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been reported with clozapine, generally at doses above 2500 mg. There have also been reports of patients recovering from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> well in excess of 4 g.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>10.2     Management of Overdosage</h2>
<p class="First">For the most up-to-date information on the management of CLOZARIL overdosage, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the , a registered trademark of Thomson PDR. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. There are no specific antidotes for CLOZARIL.
                                    <span class="Italics">**Physicians’ Desk Reference</span><span class="Sup">®</span></p>
<p>In managing overdosage, consider the possibility of multiple-drug involvement.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11     DESCRIPTION</h1>
<p class="First">CLOZARIL (clozapine), an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine. The structural formula is:
                            <span class="Sup">®</span></p>
<p><img alt="Clozapine structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cf63b13-48b2-4b07-b241-617725b52f6b&amp;name=clozaril-02.jpg"></p>
<p>CLOZARIL is available in <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow tablets of 25 mg and 100 mg for oral administration.</p>
<p>Active Ingredient: clozapine</p>
<p>Inactive Ingredients: colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch (corn), and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12     CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1     Mechanism of Action</h2>
<p class="First">The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> is mediated through antagonism of the dopamine type 2 (D ) and the serotonin type 2A (5-HT ) receptors. CLOZARIL also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.
                                    <span class="Sub">2</span><span class="Sub">2A</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2     Pharmacodynamics</h2>
<p class="First">Clozapine demonstrated binding affinity to the following receptors: histamine H (K 1.1 nM), adrenergic α (K 1.6 nM), serotonin 5-HT (K 4 nM), serotonin 5-HT (K 5.4 nM), muscarinic M (K 6.2 nM), serotonin 5-HT (K 6.3 nM), serotonin 5-HT (K 9.4 nM), dopamine D (K 24 nM), adrenergic α (K 90 nM), serotonin 5-HT (K 95 nM), serotonin 5-HT (K 120 nM), dopamine D (K 160 nM), dopamine D (K 270 nM), dopamine D (K 454 nM), and dopamine D (K 555 nM).
                                    <span class="Sub">1</span><span class="Sub">i</span><span class="Sub">1A</span><span class="Sub">i</span><span class="Sub">6</span><span class="Sub">i</span><span class="Sub">2A</span><span class="Sub">i</span><span class="Sub">1</span><span class="Sub">i</span><span class="Sub">7</span><span class="Sub">i</span><span class="Sub">2C</span><span class="Sub">i</span><span class="Sub">4</span><span class="Sub">i</span><span class="Sub">2A</span><span class="Sub">i</span><span class="Sub">3</span><span class="Sub">i</span><span class="Sub">1A</span><span class="Sub">i</span><span class="Sub">2</span><span class="Sub">i</span><span class="Sub">1</span><span class="Sub">i</span><span class="Sub">5</span><span class="Sub">i</span><span class="Sub">3</span><span class="Sub">i</span></p>
<p>Clozapine causes little or no prolactin elevation.</p>
<p>Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12p3"></a><a name="section-11.3"></a><p></p>
<h2>12.3     Pharmacokinetics</h2>
<p class="First"><span class="Italics Underline">Absorption</span></p>
<p>In man, CLOZARIL tablets (25 mg and 100 mg) are equally bioavailable relative to a CLOZARIL solution. Following oral administration of CLOZARIL 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing. The average minimum concentration at steady state was 122 ng/mL (range: 41 to 343 ng/mL), after 100 mg twice daily dosing. Food does not appear to affect the systemic bioavailability of CLOZARIL. Thus, CLOZARIL may be administered with or without food.</p>
<p><span class="Underline">Distribution</span></p>
<p>Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important .
                                    <span class="Italics">[see Drug Interactions (7)]</span></p>
<p><span class="Underline">Metabolism and Excretion</span></p>
<p>Clozapine is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and N-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4 to12 hours), compared to a mean elimination half-life of 12 hours (range: 4 to 66 hours), after achieving steady state with 100mg twice daily dosing.
                                    <span class="Italics">N-</span></p>
<p>A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady state, approximately dose-proportional changes with respect to area under the curve (AUC), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.</p>
<p><span class="Italics Underline">Drug-Drug Interaction Studies</span></p>
<p><span class="Underline">Fluvoxamine</span></p>
<p>A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations.</p>
<p><span class="Underline">Paroxetine, Fluoxetine, and Sertraline</span></p>
<p>In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations (less than 2-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.</p>
<p><span class="Italics Underline">Specific Population Studies</span></p>
<p><span class="Underline">Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>No specific pharmacokinetic studies were conducted to investigate the effects of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of clozapine. Higher clozapine plasma concentrations are likely in patients with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when given usual doses.</p>
<p><span class="Underline">CYP2D6 Poor Metabolizers</span></p>
<p>A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13     NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics Underline">Carcinogenesis</span></p>
<p>No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m body surface area basis.
                                    <span class="Sup">2</span></p>
<p><span class="Italics Underline">Mutagenesis</span></p>
<p>Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the mammalian V79 in Chinese hamster cells, the unscheduled DNA synthesis in rat hepatocytes or the micronucleus assay in mice.
                                    <span class="Italics">in vitro</span><span class="Italics">in vitro</span><span class="Italics">in vivo</span></p>
<p><span class="Italics Underline">Impairment of Fertility</span></p>
<p>Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m body surface area basis.
                                    <span class="Sup">2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14     CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14p1"></a><a name="section-13.1"></a><p></p>
<h2>14.1     Treatment Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First">The efficacy of CLOZARIL in treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least 2 of the following 4 individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions–Severity Scale score of at least 4 (moderately ill).</p>
<p>In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with CLOZARIL (N=126) or chlorpromazine (N=142). The maximum daily CLOZARIL dose was 900 mg; the mean daily dose was &gt;600 mg. The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was &gt;1200 mg.</p>
<p>The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of &lt;3 (mildly ill), or (2) a BPRS score of &lt;35, at the end of 6 weeks of treatment. Approximately 88% of patients from the CLOZARIL and chlorpromazine groups completed the 6-week trial. At the end of 6 weeks, 30% of the CLOZARIL group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p &lt;0.001). The mean change in total BPRS score was -16 and -5 in the CLOZARIL and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the CLOZARIL and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the CLOZARIL and chlorpromazine group, respectively. These changes in the CLOZARIL group were statistically significantly greater than in the chlorpromazine group (p&lt;0.001 in each analysis).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14p2"></a><a name="section-13.2"></a><p></p>
<h2>14.2     Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span></h2>
<p class="First">The effectiveness of CLOZARIL in reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> was assessed in the International <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Prevention Trial (InterSePT™, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of CLOZARIL versus olanzapine (*Zyprexa®, a registered trademark of Eli Lilly and Company) in 956 patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span> (DSM-IV) who were judged to be at risk for recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met 1 of the following criteria:</p>
<ul>
<li>They had <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span> within the 3 years prior to their baseline evaluation.</li>
<li>They had been hospitalized to prevent a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> within the 3 years prior to their baseline evaluation.</li>
<li>They demonstrated moderate-to-severe <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> with a depressive component within 1 week prior to their baseline evaluation.</li>
<li>They demonstrated moderate-to-severe <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> accompanied by command <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> to do self-harm within 1 week prior to their baseline evaluation.</li>
</ul>
<p>Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200–900 mg/day for CLOZARIL and 5–20 mg/day for olanzapine. For the 956 patients who received CLOZARIL or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.</p>
<p>The primary efficacy measure was time to (1) a significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, including a <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>; (2) hospitalization due to imminent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening? or “very much worsening? from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Monitoring Board (SMB), a group of experts blinded to patient data.</p>
<p>A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, and the remainder (38%) were diagnosed with <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>. Only about one-fourth of the total patient population (27%) was identified as “treatment-resistant? at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range 18–69). Most patients were Caucasian (71%), 15% were black, 1% were Asian, and 13% were classified as being of “other? races.</p>
<p>Patients treated with CLOZARIL had a statistically significant longer delay in the time to recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of CLOZARIL in delaying time to recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> and not a demonstration of the superior efficacy of CLOZARIL over olanzapine.</p>
<p>The probability of experiencing (1) a significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, including a <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, or (2) hospitalization because of imminent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for CLOZARIL patients than for olanzapine patients at Week 104: CLOZARIL 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 2).</p>
<p><span class="Bold">Figure 2. Cumulative Probability of a Significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">Suicide Attempt</span> or Hospitalization to Prevent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> in Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span> at High Risk of Suicidality</span></p>
<p><img alt="Figure 2:  Kaplan Meier Estimates of Cumulative Probability of a Significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">Suicide Attempt</span> or Hospitalization to Prevent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cf63b13-48b2-4b07-b241-617725b52f6b&amp;name=clozaril-03.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16     HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:64725-1260-1 in a CONTAINER of 30 TABLETS</p>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14.1"></a><p></p>
<h2>16.1     How Supplied</h2>
<p class="First">CLOZARIL® (clozapine) is available as 25 mg and 100 mg round, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow, uncoated tablets with a facilitated score on one side.</p>
<table>
<col width="500">
<col width="200">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold Italics">CLOZARIL® (clozapine) Tablets</span></td>
<td></td>
</tr>
<tr>
<td><span class="Bold Italics">25 mg</span></td>
<td></td>
</tr>
<tr>
<td>Engraved with “CLOZARIL? once on the periphery of one side.</td>
<td></td>
</tr>
<tr>
<td>Engraved with a facilitated score and “25? once on the other side.</td>
<td></td>
</tr>
<tr>
<td class="Botrule">Bottle of 100</td>
<td class="Botrule">NDC 0078-0126-05</td>
</tr>
<tr>
<td class="Botrule">Bottle of 500</td>
<td class="Botrule">NDC 0078-0126-08</td>
</tr>
<tr>
<td class="Botrule">Unit dose packages of 100: 2 x 5 strips, 10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> per strip</td>
<td class="Botrule">NDC 0078-0126-06</td>
</tr>
<tr>
<td><span class="Bold Italics">100 mg</span></td>
<td></td>
</tr>
<tr>
<td>Engraved with “CLOZARIL? once on the periphery of one side.</td>
<td></td>
</tr>
<tr>
<td>Engraved with a facilitated score and “100? once on the other side.</td>
<td></td>
</tr>
<tr>
<td class="Botrule">Bottle of 100</td>
<td class="Botrule">NDC 0078-0127-05</td>
</tr>
<tr>
<td class="Botrule">Bottle of 500</td>
<td class="Botrule">NDC 0078-0127-08</td>
</tr>
<tr class="Last">
<td class="Botrule">Unit dose packages of 100: 2 x 5 strips, 10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> per strip</td>
<td class="Botrule">NDC 0078-0127-06</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.2"></a><p></p>
<h2>16.2     Storage and Handling</h2>
<p class="First">Storage temperature should not exceed 30°C (86°F).</p>
<p>Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17     PATIENT COUNSELING INFORMATION</h1>
<p class="First">Discuss the following issues with patients and caregivers:</p>
<ul>
<li>Prior to initiating treatment, educate patients and caregivers about the significant risk of developing <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Advise them to immediately report the appearance of signs or symptoms consistent with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; mucus membrane <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>; skin, pharyngeal, vaginal, urinary, or pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; or extreme <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>) at any time during CLOZARIL therapy .
                                <span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>:</span><span class="Italics">[see Boxed Warning and Warnings and Precautions (5.1)]</span><ul><li>Inform patients and caregivers that CLOZARIL will be made available only through a special program (CLOZARIL National Registry) designed to ensure the required blood monitoring, in order to reduce the risk of developing <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Inform patients and caregivers the WBC count and ANC will be monitored as follows:
                                        <ul>
<li>Weekly blood tests are required for the first 6 months.</li>
<li>If acceptable WBC counts and ANCs (WBC count ≥3500/mm and ANC ≥2000/mm ) have been maintained during the first 6 months of continuous therapy, then WBC counts and ANCs can be monitored every 2 weeks for the next 6 months.
                                                <span class="Sup">3</span><span class="Sup">3</span>
</li>
<li>Thereafter, if acceptable WBC counts and ANCs have been maintained during the second 6 months of continuous therapy, WBC counts and ANCs can be monitored every 4 weeks.</li>
</ul>
</li></ul>
</li>
<li>Inform patients and caregivers about the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the period of initial dose titration. Instruct them to strictly follow the clinician’s instructions for dosage and administration. Advise patients to consult their clinician immediately if they feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lose consciousness or have signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> .
                                <span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>:</span><span class="Italics">[see Dosage and Administration (2.2) and Warnings and Precautions (5.3)]</span>
</li>
<li>Inform patients and caregivers about the significant risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during CLOZARIL treatment. Caution them about driving and any other potentially hazardous activity while taking CLOZARIL .
                                <span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span><span class="Italics">[see Warnings and Precautions (5.4)]</span>
</li>
<li>Advise patients to consult their clinician immediately if they feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lose consciousness or have signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Instruct patients to not take CLOZARIL with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking CLOZARIL before any new drug .
                                <span class="Italics Underline">QT Interval Prolongation:</span><span class="Italics">[see Warnings and Precautions (5.8.) and Drug Interactions (7.1)]</span>
</li>
<li>Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and cardiovascular reactions. Educate patients and caregivers about the symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (high blood sugar) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Monitor all patients for these symptoms. Patients who are diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or have risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (<span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> should have assessments of fasting glucose. Clinical monitoring of weight is recommended .
                                <span class="Italics Underline">Metabolic Changes (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>):</span><span class="Italics">[see Warnings and Precautions (5.9)]</span>
</li>
<li>Because CLOZARIL may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that CLOZARIL therapy does not affect them adversely .
                                <span class="Italics Underline">Interference with Cognitive and Motor Performance:</span><span class="Italics">[see Warnings and Precautions (5.14)]</span>
</li>
<li>Inform patients and caregivers that if the patient misses taking CLOZARIL for more than 2 days, they should not restart their medication at the same dosage but should contact their physician for dosing instructions adversely .
                                <span class="Italics Underline">Missed Doses and Re-initiating Treatment:</span><span class="Italics">[see Dosage and Administration (2.5) and Warnings and Precautions (5.3)]</span>
</li>
<li>Patients and caregivers should notify the clinician if the patient becomes pregnant or intends to become pregnant during therapy .
                                <span class="Italics Underline">Pregnancy:</span><span class="Italics">[see Use in Specific Populations (8.1)]</span>
</li>
<li>Advice patients and caregivers that the patient should not breast feed an infant if they are taking CLOZARIL [see Use in Specific Populations (8.3)].
                                <span class="Italics Underline">Nursing:</span>
</li>
<li>Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions .
                                <span class="Italics Underline">Concomitant Medication:</span><span class="Italics">[see Dosage and Administrations (2.6) and Drug Interactions (7.1)]</span>
</li>
</ul>
<p>*Zyprexa® (olanzapine) is a registered trademark of Eli Lilly and Company.</p>
<p>**Trademark of Thomson Healthcare, Inc.</p>
<p>CLOZARIL® is a registered trademark of Novartis Pharmaceuticals Corporation.</p>
<p>Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936
                            <br></p>
<p>© Novartis</p>
<p>T2013-114 November 2013
                            <br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cf63b13-48b2-4b07-b241-617725b52f6b&amp;name=64725-1260.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLOZARIL 		
					</strong><br><span class="contentTableReg">clozapine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64725-1260(NDC:0078-0126)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOZAPINE</strong> (CLOZAPINE) </td>
<td class="formItem">CLOZAPINE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CLOZARIL;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64725-1260-1</td>
<td class="formItem">30  in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019758</td>
<td class="formItem">09/30/1989</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>TYA Pharmaceuticals
							(938389038)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>TYA Pharmaceuticals (938389038)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TYA Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">938389038</td>
<td class="formItem">RELABEL(64725-1260), REPACK(64725-1260)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>089b76b6-71af-4893-bb1b-4890fcc4a3e5</div>
<div>Set id: 0cf63b13-48b2-4b07-b241-617725b52f6b</div>
<div>Version: 2</div>
<div>Effective Time: 20131113</div>
</div>
</div> <div class="DistributorName">TYA Pharmaceuticals</div></p>
</body></html>
